

ChemoCentryx, Inc. Investor Relations Department 850 Maude Avenue Mountain View, CA 94043 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: CCXI	
Last Trade:	7.21
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.01 🕇 (+0.139%)
Day Range	6.92 - 7.28
52-Week Range	5.15 - 10.80
Volume	131,540

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ChemoCentrvx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases. inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemoattractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing ... (more)

Stock Performance



Press Releases [View all]

Sep 5, 2017

<u>ChemoCentryx to Present at Three</u> Upcoming Investor Conferences

Aug 8, 2017

<u>ChemoCentryx Reports Second Quarter</u> 2017 Financial Results and Recent Highlights

Jul 26, 2017

<u>ChemoCentryx to Hold Second Quarter 2017</u> <u>Financial Results Conference Call on</u> Tuesday, August 8, 2017

Jun 6, 2017

Oral Presentations at ERA-EDTA Congress
Highlight Fourth Potential Indication for
Avacopan and Potential for CCR2 Inhibition
in Focal Segmental Glomerulosclerosis
(FSGS)

May 24, 2017

<u>ChemoCentryx to Present at Two Upcoming</u> Investor Conferences

Upcoming Events [View all]

Sep 26, 2017 10:30 AM ET

Ladenburg Thalmann 2017 Healthcare
Conference

Sep 27, 2017 2:15 PM ET
Cantor Fitzgerald 2017 Global Healthcare
Conference

Financials [View all]

Mar 14, 2017 Annual Report (10-K)

Apr 10, 2017
Proxy Statement (DEF 14A)

Aug 8, 2017

Quarterly Report (10-Q)

May 10, 2017

Quarterly Report (10-Q)

Nov 8, 2016 Quarterly Report (10-Q)